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Assessment of Myocardial Scarring
Improves Risk Stratification in Patients
Evaluated for Cardiac Defibrillator Implantation
Igor Klem, MD,*† Jonathan W. Weinsaft, MD,*† Tristram D. Bahnson, MD,† Don Hegland, MD,*†
Han W. Kim, MD,*† Brenda Hayes, BS,* Michele A. Parker, MS,*† Robert M. Judd, PHD,*†‡
Raymond J. Kim, MD*†‡
Durham, North Carolina
Objectives We tested whether an assessment of myocardial scarring by cardiac magnetic resonance imaging (MRI) would
improve risk stratification in patients evaluated for implantable cardioverter-defibrillator (ICD) implantation.
Background Current sudden cardiac death risk stratification emphasizes left ventricular ejection fraction (LVEF); however,
most patients suffering sudden cardiac death have a preserved LVEF, and many with poor LVEF do not benefit
from ICD prophylaxis.
Methods One hundred thirty-seven patients undergoing evaluation for possible ICD placement were prospectively enrolled
and underwent cardiac MRI assessment of LVEF and scar. The pre-specified primary endpoint was death or ap-
propriate ICD discharge for sustained ventricular tachyarrhythmia.
Results During a median follow-up of 24 months the primary endpoint occurred in 39 patients. Whereas the rate of ad-
verse events steadily increased with decreasing LVEF, a sharp step-up was observed for scar size 5% of left
ventricular mass (hazard ratio [HR]: 5.2; 95% confidence interval [CI]: 2.0 to 13.3). On multivariable Cox propor-
tional hazards analysis, including LVEF and electrophysiological-study results, scar size (as a continuous variable
or dichotomized at 5%) was an independent predictor of adverse outcome. Among patients with LVEF 30%,
those with significant scarring (5%) had higher risk than those with minimal or no (5%) scarring (HR: 6.3;
95% CI: 1.4 to 28.0). Those with LVEF 30% and significant scarring had risk similar to patients with LVEF
30% (p  0.56). Among patients with LVEF 30%, those with significant scarring again had higher risk than
those with minimal or no scarring (HR: 3.9; 95% CI: 1.2 to 13.1). Those with LVEF 30% and minimal scarring
had risk similar to patients with LVEF 30% (p  0.71).
Conclusions Myocardial scarring detected by cardiac MRI is an independent predictor of adverse outcome in patients being
considered for ICD placement. In patients with LVEF 30%, significant scarring (5% LV) identifies a high-risk
cohort similar in risk to those with LVEF 30%. Conversely, in patients with LVEF 30%, minimal or no scarring
identifies a low-risk cohort similar to those with LVEF 30%. (J Am Coll Cardiol 2012;60:408–20) © 2012 by
the American College of Cardiology Foundation
Published by Elsevier Inc. http://dx.doi.org/10.1016/j.jacc.2012.02.070Sudden cardiac death (SCD) is a leading cause of mortality
responsible for approximately 325,000 deaths annually in
the United States alone (1). Currently, risk stratification for
SCD emphasizes left ventricular ejection fraction (LVEF),
and significant left ventricular (LV) dysfunction has become
the primary basis for determining the eligibility of a patient
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However, LVEF has limitations in predicting clinical
events. Sudden cardiac death typically results from ventricular
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July 31, 2012:408–20 Myocardial Scarring and ICD Risk Stratificationtachyarrhythmias (6), and LVEF provides an indirect measure
of the arrhythmic potential. Not surprisingly, in population
studies, up to 70% of patients suffering SCD have a preserved
LVEF and are not identified for prophylactic ICD insertion
(7). By contrast, in patients with poor LVEF—who are eligible
or ICD prophylaxis—many do not benefit. Recent trials
uggest that approximately 14 to 18 patients with ventric-
lar dysfunction need to have an ICD implanted to prevent
death (3,5). Moreover, considering the substantial cost (8)
nd the potential for complications (9), improved risk
tratification to identify patients who would benefit most
rom ICD implantation remains an important public health
hallenge.
Myocardial scar tissue is known to serve as a substrate for
alignant ventricular tachyarrhythmias in both ischemic
10,11) and nonischemic cardiac disorders (12,13). Impor-
antly, the presence and extent of scarring might not be
oncordant with LVEF. For instance, some patients with
xtensive scarring might have preserved LVEF either be-
ause the scar is not full-thickness and/or because there is
yperkinesia of remote segments (14,15). Conversely, some
atients without myocardial scarring might have severely
educed LVEF (16,17).
We postulated that an assessment of myocardial scarring
ould improve risk stratification for SCD beyond that pro-
ided by LVEF. Delayed-enhancement cardiovascular mag-
etic resonance (DE-CMR) provides high spatial resolu-
ion images of scar tissue that directly correlate with
athology (18,19). Additionally, DE-CMR has shown
rognostic utility above and beyond common clinical and
unctional indexes in a variety of cohorts with ischemic
20–23) or nonischemic (19,20,24) cardiac disorders. How-
ver, in most studies evaluating prognosis, there were few
ard events, and the primary endpoint was a composite
ncluding hospitalization for heart failure. Thus, additional
tudies evaluating the prognostic value of DE-CMR are
ssential.
The present investigation was designed to directly
ompare the predictive value of scar to LVEF— both
imultaneously assessed during the same cardiac magnetic
esonance imaging (MRI) session—for adverse outcome
n patients being considered for ICD implantation.
ethods
opulation and design. We prospectively screened pa-
ients referred to the electrophysiology service and sched-
led for an electrophysiology study (EPS) and/or ICD
lacement between July 1, 2002, and July 1, 2004. Because
e wished to evaluate both patients with preserved LVEF
nd those with impaired LVEF, a broad population was
hosen and only those with contraindications for cardiac
RI (prior pacemaker or defibrillator) or were under 18
ears of age were excluded. The reasons for referral to the
lectrophysiology service were low ejection fraction meeting triteria for an ICD in 69 (50%)
atients; mild LV dysfunction
ot meeting criteria but with pal-
itations, frequent premature
entricular contractions, and/or
onsustained ventricular tachy-
ardia in 22 (16%); evaluation of
ide-complex tachycardia in 25
18%); syncope in 17 (13%); and
resumed cardiac arrest in 4 (3%).
f the 137 patients that were en-
olled, cardiac MRI was per-
ormed for research purposes (only
his specific protocol) in 109 pa-
ients, and scan results were not
sed to guide clinical decision-
aking. The remaining 28 pa-
ients were screened concurrently
nd in the same prospective man-
er but had a clinically ordered
can for the assessment of LVEF.
his group was similar to the 109
canned only for the purpose of
esearch with respect to age, sex,
revalence of coronary artery dis-
ase (CAD), LVEF, prevalence
nd extent of scar, as well as
linical outcome during follow-up (all p  0.10). All
atients gave written informed consent. The study was
pproved by the Duke Institutional Review Board.
A comprehensive medical history including CAD risk
actors, heart failure functional class (New York Heart
ssociation [NYHA]), and medications at the time of
ardiac MRI was obtained in all patients. Additionally,
2-lead electrocardiography was performed a median of 2
ays (interquartile range [IQR]: 1 to 5 days) from cardiac
RI and interpreted blinded to clinical and cardiac MRI
ata. Established criteria (3) were used to categorize pa-
ients as having ischemic or nonischemic heart disease:
schemic disease was considered present if there was 70%
tenosis of a major epicardial coronary artery on x-ray
ngiography (25), history of enzymatically proven myocar-
ial infarction, or evidence of ischemia or infarction on
linical stress-testing. Most patients (n  122, 89%) had
reviously undergone x-ray coronary angiography.
ollow-up. Information concerning arrhythmic events and
ortality status were obtained at regular intervals of 6
onths via: 1) telephone interview with the patient or, if
eceased, with family members; 2) contact with the physi-
ian(s) of the patient; and 3) hospital records. Additionally,
n patients with ICDs, stored electrograms were down-
oaded at 3-month intervals and reviewed by an electro-
hysiologist blinded to clinical data and cardiac MRI
ndings. The pre-specified primary endpoint was all-cause
ortality or appropriate ICD discharge for ventricular
Abbreviations
and Acronyms
CAD  coronary artery
disease
CI  confidence interval
DE-CMR  delayed-
enhancement
cardiovascular magnetic
resonance
EPS  electrophysiology
study
HR  hazard ratio
ICD  implantable
cardioverter-defibrillator
IQR  interquartile range
LV  left ventricular
LVEF  left ventricular
ejection fraction
MRI  magnetic resonance
imaging
NYHA  New York Heart
Association
SCD  sudden cardiac
death
VT  ventricular
tachycardiaachycardia or fibrillation (26). There were 2 secondary
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Myocardial Scarring and ICD Risk Stratification July 31, 2012:408–20endpoints: 1) all-cause mortality alone; and 2) SCD or
appropriate ICD discharge. For the primary endpoint,
all-cause rather than cardiac mortality was included (as
recommended by a policy statement on endpoints for trials
that include ICDs written by the North American Society
for Pacing and Electrophysiology) (27), because the former
is objective, clinically relevant, and unbiased, which is often
not the case for cardiac mortality (28). The secondary
endpoint of SCD or appropriate ICD discharge was in-
cluded to explore the mechanism of adverse outcome, and
SCD was defined as death within 1 h of symptom onset or
an unobserved death in which the patient was seen and
known to be doing well within 24 h of death (29). All event
information was obtained and classified without knowledge
of clinical or cardiac MRI findings.
Patients were enrolled before the recent Food and Drug
Administration alerts regarding the rare occurrence of
nephrogenic systemic fibrosis associated with gadolinium
contrast administration (30). Two patients had end-stage
renal disease and were receiving dialysis (1 hemodialysis, 1
peritoneal dialysis) at the time of enrollment. None of the
study participants developed nephrogenic systemic fibrosis
during the follow-up period.
Cardiovascular MRI. ACQUISITION. Clinical 1.5-T scan-
ers (Siemens Sonata or Avanto; Siemens, Malvern, Penn-
ylvania) with phased-array receiver coils and standard
rotocols were used (31). Briefly, cine images were acquired
n multiple short-axis (every 10 mm throughout the entire
V) and 3 long-axis views with a steady-state free preces-
ion sequence (slice thickness, 6 mm; inter-slice gap, 4 mm;
epetition time, 3.0 ms; echo time, 1.5 ms; temporal
esolution, 35 to 40 ms; flip angle, 60°; in-plane resolution
.7  1.4 mm). DE-CMR was performed with a seg-
ented inversion-recovery gradient-echo sequence (slice
hickness, 6 mm; inter-slice gap, 4 mm; repetition time, 9.5
s; echo time, 3.8 ms; flip angle, 25°; in-plane resolution
.8  1.4 mm) 10 min after contrast administration (gado-
ersetamide, 0.15 mmol/kg) in the identical locations as
ine-cardiac MRI. Inversion delay time was set to null signal
rom normal myocardium and was typically 280 to 360 ms.
ANALYSIS. Cine-cardiac MRI and DE-CMR images were
evaluated separately masked to all patient information. Left
ventricular volumes, mass, and ejection fraction were quan-
titatively measured from the stack of short-axis cine images
using standard techniques (32). Presence or absence of LV
aneurysm was noted. The presence and location of hyper-
enhanced tissue on DE-CMR, which was interpreted as
representing scarred myocardium (31), was determined by
visual inspection with the American Heart Association
17-segment model (33). Regional enhancement was scored
according to the spatial extent of hyperenhanced tissue
within each segment (0 no hyperenhancement, 1 1% to
25% hyperenhanced, 2  26% to 50%, 3  51% to 75%,
4  76% to 100%) (14). Scar size was measured by
planimetry from the stack of short-axis DE-CMR images inour cardiac MRI core laboratory by a single blinded reader.
Inter- and intra-observer agreement for scar size is routinely
tested in the core laboratory for quality assurance; Bland-
Altman analysis demonstrated a bias of 1.0% and 0.1%,
respectively, with an SD of differences of 2.6% and 0.8%,
respectively (22); the intra-class correlation coefficients were
0.942 and 0.982, respectively. We also assessed other
morphological characteristics of scar. These included the
number of separate scars, scar surface area (determined from
the scar circumference on the stack of short-axis DE-CMR
images [34]), and scar pattern (classified as CAD-type when
subendocardial or transmural in a typical vascular distribu-
tion or non-CAD-type when mid-myocardial or epicardial
[35]). The extent of the “gray-zone” (i.e., regions with
partial hyperenhancement) was also determined (36). As
described previously (36), gray zones were defined as those
regions with image intensity between 2 and 3 SD above that
of reference, remote myocardium and expressed as a per-
centage of LV mass.
Electrophysiological testing. A total of 105 (77%) pa-
tients underwent EPS within a median of 0 days (IQR: 0 to
3.5 days) of cardiac MRI. No patient experienced a change
in clinical status in the time between cardiac MRI and EPS.
The EPS was performed with standard techniques. Briefly,
programmed stimulation was performed with 2 drive trains
followed by 1 to 3 ventricular extrastimuli that were 2 ms in
duration at twice the diastolic threshold at 2 right ventric-
ular sites (37). All EPS data were reinterpreted at a later
timepoint by an experienced electrophysiologist blinded to
patient information and cardiac MRI findings by reviewing
the intracardiac electrograms and the surface electrocardio-
graphy stored on the commercial recording system (Prucka
Cardiolab, GE Healthcare, Piscataway, New Jersey). The
EPS endpoint included the induction of a sustained mono-
morphic ventricular tachycardia (VT), polymorphic VT, or
ventricular fibrillation or completion of the protocol (37).
Definitions were similar to those of previous studies: a
sustained ventricular arrhythmia was defined as one lasting
30 s or requiring termination sooner because of hemody-
namic compromise; monomorphic VT was defined as a VT
with a uniform beat-to-beat QRS morphology; polymor-
phic VT had a variable QRS morphology; and ventricular
fibrillation was defined as a rapid, disorganized rhythm
without consistently identifiable complexes (37).
Statistical analysis. Normally distributed data are pre-
sented as the mean SD or, in cases where the distribution
is not normal, as median and IQR. Two sample t tests were
used to compare mean values of continuous data between 2
groups. Chi-square tests were used to compare discrete data
between groups; in those cases where the expected cell count
was 5, Fisher exact test was used. Cumulative event rates
were calculated according to the Kaplan-Meier method.
Differences in event rates between groups were assessed
with the log-rank test without adjustment for multiple
comparisons. To identify the baseline characteristics asso-
ciated with adverse outcome, univariable Cox proportional
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July 31, 2012:408–20 Myocardial Scarring and ICD Risk Stratificationhazards regression analysis was performed. For patients with
2 or more events during follow-up (several arrhythmic
events or an arrhythmic event followed by death), only the
time to the first event was considered per patient. Because
coronary revascularization might result in procedure-related
myocardial injury (38,39), patients who underwent coronary
bypass graft surgery or percutaneous coronary intervention
after study enrollment were censored at the date of the
procedure. Patients were to be censored on the date of heart
transplantation, but none underwent heart transplantation
during follow-up.
Two Cox regression multivariable models were subse-
quently developed. In the first, candidate variables showing
a possible association with prognosis by univariable analysis
(p  0.10) were considered one-at-a-time starting with the
ost significant variable. Significant variables were deter-
ined by stepwise selection (and backward elimination) at
he 0.05 level of significance. In the subgroup with EPS a
eparate analysis was performed with monomorphic VT
dded as a covariate. Relative risks were expressed as hazard
atios (HRs) with associated 95% confidence intervals (CIs).
n the second multivariable model, only 3 variables were
ncluded to avoid the potential for overfitting. These were
YHA functional class (the most significant clinical pre-
ictor), LVEF, and scar size 5%. Formal risk reclassifica-
ion analyses were conducted with both integrated discrim-
nation improvement (IDI) and net reclassification
mprovement (NRI) methods (40). All statistical tests were
-tailed, and p  0.05 was regarded as significant.
esults
aseline characteristics. Of the 137 enrolled patients, all
uccessfully underwent cardiac MRI, and their baseline
haracteristics are shown in Table 1. Briefly, the mean age
as 59 years, 63% were male, approximately one-half (53%)
ad ischemic heart disease, and the mean LVEF was 35%.
ust over 60% had NYHA functional class II or higher, and
wo-thirds were treated with a beta-blocker and an
ngiotensin-converting enzyme inhibitor or angiotensin re-
eptor blocker. Most (n  105) underwent EPS, and
onomorphic VT was induced in 21 (20%) patients.
yocardial scar was found in 107 patients (78%) with a
edian scar size of 7.8% of the LV mass (IQR: 1.1% to
5.8%). Patients with ischemic heart disease were older;
ore often male; more likely to have diabetes, hypertension,
nd hypercholesterolemia; and had lower LVEF and higher
revalence of myocardial scar, compared with those without
schemic disease.
ollow-up. The median follow-up time was 24 months
IQR: 19.9 to 29.0 months). No patient was lost to
ollow-up. One hundred four patients (75%) had an ICD
laced, generally during the initial evaluation, 2 days (IQR:
to 7 days) after enrollment. The decision for ICD
mplantation was guided by standard consensus criteria
2,41) including LVEF and EPS results but was at theiscretion of the treating physician after discussion with the
atient. The indication for ICD implantation was primary
rophylaxis in 92 patients and secondary prophylaxis (sus-
ained VT or presumed cardiac arrest) in 12. The primary
ndpoint of death or appropriate ICD discharge occurred in
9 (28%) patients: 19 died (5 of whom also had an ICD
ischarge), and 20 had ICD discharge only. Sudden cardiac
eath occurred in 5 patients. Four patients underwent
evascularization (all percutaneous coronary interventions)
t 9, 12, 12, and 21 months after enrollment and were
ensored at that time.
redictors of adverse events. Patient characteristics re-
ated to the primary endpoint are listed in Table 1. Patients
ho died or had an appropriate ICD discharge were more
ikely to have ischemic heart disease, worse NYHA functional
lass, and monomorphic VT elicited on EPS. Patients with
vents had, among the cardiac MRI parameters, worse LVEF
nd larger end-diastolic and end-systolic volumes and more
requently had an LV aneurysm. Additionally, they were more
ikely to have myocardial scar, and scar size as a percentage of
V mass was larger compared with patients without events.
Figure 1A details the relationship between LVEF and
vents. For each decrement in LVEF, there was a mono-
onically increasing event rate. Figure 1B demonstrates a
ifferent relationship between scar size and events. There
as a marked step-up in event rate in patients with a scar
ize exceeding 5% of LV mass (HR: 5.2, 95% CI: 2.0 to
3.3, p  0.0006), without further rise with each increment
n scar size. Among the 84 patients with scar 5%, 34 had
vents—17 died (4 of whom also had an ICD discharge),
nd 17 had ICD discharge only—representing an event rate
f 19.6%/year and a mortality rate of 9.8%/year. Conversely,
mong the 53 patients with scar5%, 5 had events—2 died
1 of whom also had an ICD discharge), and 3 had ICD
ischarge only—representing an event rate of 4.25%/year
nd a mortality rate of 1.7%/year. Among the 30 patients
ithout any myocardial scar, there were 2 events (both ICD
ischarges, no deaths) representing a total event rate of
.8%/year.
The HRs for the significant clinical and cardiac MRI
redictors of adverse events are shown in Table 2. For the
rimary endpoint of death or ICD discharge, multivariable
nalysis demonstrated that NYHA functional class (HR:
.7, 95% CI: 1.2 to 2.4, p 0.003) and scar size5% (HR:
4.6, 95% CI: 1.8 to 11.8, p  0.002) were the only
independent predictors. Scar size 5% remained an inde-
pendent predictor for the secondary endpoints of SCD or
ICD discharge and all-cause mortality. Notably, although
LVEF was a significant univariable predictor of adverse
events (primary and both secondary endpoints), it was not
an independent predictor on multivariable analysis, either as
a continuous variable or with a cutoff of 30% or 35%.
Multivariable analysis excluding the 28 patients with a clini-
cally ordered scan demonstrated the same independent predic-
tors as in the entire population. For the primary endpoint,
NYHA functional class (HR: 1.9, 95% CI: 1.3 to 2.9, p 
0m
i
I
a
r; LV
V
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.003) again were the only independent predictors.
When scar size was included as a continuous (% LV
Baseline Patient CharacteristicsTable 1 Baseline Patient Characteristics
Characteristic
All Patients
(N  137)
Death or ICD Discharge
(n  39)
N
Age (yrs) 59.2 15.1 61.6 15.9
Male 86 (63%) 26 (67%)
Clinical history
Diabetes mellitus 32 (23%) 13 (33%)
Hypertension 73 (53%) 23 (59%)
Cigarette smoker 25 (18%) 9 (23%)
Hypercholesterolemia 67 (49%) 21 (54%)
Ischemic heart disease 73 (53%) 26 (67%)
Prior revascularization 54 (39%) 16 (41%)
CABG 38 (70%) 11 (69%)
PCI 16 (30%) 5 (31%)
Prior myocardial infarction* 48 (35%) 15 (38%)
NYHA functional class†
I 51 (37%) 7 (18%)
II 34 (25%) 10 (26%)
III 45 (33%) 17 (44%)
IV 7 (5%) 5 (13%)
Medications
ACE inhibitor 75 (55%) 22 (56%)
ARB 15 (11%) 6 (15%)
Antiarrhythmic class I 2 (1%) 1 (3%)
Antiarrhythmic class III 16 (12%) 4 (10%)
Antiplatelet 96 (70%) 30 (77%)
Beta-blocker 92 (67%) 31 (79%)
Calcium-channel blocker 18 (13%) 4 (10%)
Digitalis 36 (26%) 11 (28%)
Diuretics 71 (52%) 24 (62%)
Spironolactone 31 (23%) 10 (26%)
Statin 66 (48%) 19 (49%)
Electrocardiogram
Heart rate (beats/min) 74.0 14.8 77.6 15.3
QRS (ms) 111.9 31.8 116.2 29.9
Left bundle branch block 21 (16%) 7 (18%)
Right bundle branch block 18 (13%) 5 (13%)
Electrophysiological study§
Monomorphic VT 21 (20%) 10 (34%)
Polymorphic VT or VF 22 (21%) 5 (17%)
Non inducible 57 (54%) 14 (48%)
Cardiac MRI
LVEF (%) 35.3 18.1 27.9 14.3
LV EDV (ml) 207.7 111.0 246.0 155.5
LV ESV (ml) 147.7 110.6 190.0 152.2
LV mass (g) 196.8 71.0 201.2 73.1
LV aneurysm 12 (9%) 6 (21%)
Any scar on DE-CMR 107 (78%) 37 (95%)
Scar size (% of LV mass) 7.8 (1.1–15.8) 12.9 (6.3–19.2)
Values are mean SD, n (%), or median (interquartile range). *10 patients with subacute infarction (
class was documented at time of hospital admission; p value pertains to the comparison between the gr
according to NYHA class. ‡Fisher exact test (2-tailed). §Performed in 105 patients. Includes 5 patien
ACE angiotensin-converting-enzyme; ARB angiotensin receptor blocker; CABG coronary a
EDV end-diastolic volume; ESV end-systolic volume; ICD implantable cardioverter-defibrillato
F  ventricular fibrillation; VT  ventricular tachycardia.ass) rather than dichotomous variable, it remained an 1ndependent predictor of the primary endpoint, death or
CD discharge (HR: 1.03, 95% CI: 1.01 to 1.07, p  0.03),
nd the secondary endpoint, SCD or ICD discharge (HR:
th or ICD Discharge
(n  98) p Value
CAD
(n  73)
No CAD
(n  64) p Value
58.2 14.9 0.23 65.3 10.9 52.3 16.2 0.0001
60 (61%) 0.55 54 (74%) 32 (50%) 0.004
19 (19%) 0.08 27 (37%) 5 (8%) 0.0001
50 (51%) 0.40 49 (67%) 24 (38%) 0.0005
16 (16%) 0.36 16 (22%) 9 (14%) 0.24
46 (47%) 0.47 55 (75%) 12 (19%) 0.0001
47 (47%) 0.04 — —
38 (39%) 0.81 — —
27 (71%) 0.94 — —
11 (29%) 0.79 — —
33 (34%) 0.60 — —
0.003 0.15
44 (45%) 21 (29%) 30 (47%)
24 (24%) 21 (29%) 13 (20%)
28 (29%) 26 (36%) 19 (27%)
2 (2%) 5 (7%) 2 (3%)
53 (54%) 0.80 44 (66%) 31 (48%) 0.16
9 (9%) 0.24 9 (12%) 6 (9%) 0.58
1 (1%) 0.49‡ 0 (0%) 2 (3%) 0.12‡
12 (12%) 0.78‡ 8 (11%) 8 (13%) 0.78‡
66 (67%) 0.27 63 (86%) 33 (52%) 0.0001
61 (62%) 0.053 57 (78%) 35 (55%) 0.004
14 (14%) 0.59‡ 7 (10%) 11 (17%) 0.19‡
25 (26%) 0.75 21 (29%) 15 (23%) 0.48
47 (48%) 0.15 42 (58%) 29 (45%) 0.15
21 (21%) 0.60 18 (25%) 13 (20%) 0.54
47 (48%) 0.94 51 (70%) 15 (23%) 0.0001
72.6 14.3 0.07 72.4 13.4 75.8 16.0 0.18
110.3 32.4 0.33 115.2 30.3 108.3 33.2 0.21
14 (14%) 0.57 11 (15%) 10 (16%) 0.92
13 (13%) 0.97 10 (14%) 8 (13%) 0.84
11 (14%) 0.02 15 (28%) 6 (11%) 0.02
17 (22%) 0.56 14 (27%) 8 (15%) 0.14
43 (57%) 0.45 33 (44%) 24 (45%) 0.89
38.3 18.8 0.002 30.5 14.0 40.9 20.6 0.0008
192.4 83.5 0.048 224.0 98.9 183.0 90.6 0.13
130.9 84.1 0.03 165.1 96.8 122.1 94.2 0.01
194.9 70.4 0.64 204.4 63.1 186.8 76.4 0.14
6 (6%) 0.01 10 (14%) 2 (3%) 0.03
70 (71%) 0.003 70 (96%) 37 (58%) 0.0001
5.2 (0.0–14.7) 0.002 13.9 (6.2–19.3) 1.9 (0.0–8.5) 0.0001
of cardiac magnetic resonance imaging (MRI) study). †New York Heart Association (NYHA) functional
ith andwithout events andwith andwithout coronary artery disease (CAD) in the distribution of patients
ut structural heart disease in whom bundle branch re-entry tachycardia was induced.
pass graft surgery; DE-CMR delayed enhancement cardiovascular magnetic resonance imaging;
left ventricular; LVEF left ventricular ejection fraction; PCI percutaneous coronary intervention;o Dea
30 days
oups w
ts witho
rtery by.04, 95% CI: 1.01 to 1.07, p  0.03).
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July 31, 2012:408–20 Myocardial Scarring and ICD Risk StratificationAn analysis of the subgroup of patients undergoing EPS
(n  105) was performed after including inducible mono-
orphic VT as a covariate (Table 2). Scar size 5% was an
independent predictor for all endpoints. Inducible mono-
morphic VT was a significant univariable predictor of death
or ICD discharge and SCD or ICD discharge but not
all-cause death. On multivariable analysis, inducible mono-
morphic VT was not an independent predictor of the
primary or secondary endpoints.
In a separate multivariable modeling approach, only 3
variables (NYHA functional class, LVEF, and scar size
5%) were included to avoid the potential for overfitting. In
this model, scar size 5% was the strongest predictor of the
primary endpoint (HR: 4.5, 95% CI: 1.7 to 11.6, p 
0.002). Although NYHA functional class was an indepen-
dent predictor (HR: 1.6, 95% CI: 1.0 to 2.4, p  0.04),
LVEF was not (HR: 0.1, 95% CI: 0.97 to 1.20, p  0.58).
To assess the incremental prognostic value of the scar
data over NYHA functional class and over LVEF, we
performed a risk reclassification analysis for the primary
endpoint. The IDI showed significant reclassification when
adding scar data to the model with NYHA functional class
(IDI  0.134, p  0.0004) and when adding scar data to
he model with LVEF (IDI  0.111, p  0.003). The NRI
was calculated with 4 risk categories (0% to 20%, 20% to
40%, 40% to 60%, and 60%) and also showed significant
reclassification when adding scar data to the model with
NYHA functional class (NRI  41%, p  0.03) and to the
odel with LVEF (NRI  32%, p  0.049).
mproved risk stratification in LVEF subgroups. Sur-
ival analysis in subgroups with LVEF 30% and 30%
5,42) are shown in Figures 2 and 3, respectively. Among
atients with LVEF 30%, those with significant scarring
5%) had higher incidence of death or ICD discharge
Figure 1 Event Rate Depending on LVEF and Scar Size
The percentage of patients with the primary endpoint of death or appropriate impla
left ventricular ejection fraction (LVEF) (A) and scar size (B). For ejection fraction,
event rate monotonically increases with decreasing LVEF. In contrast, a marked st
ever does not rise further with increasing scar size.ompared with those with minimal or no (5%) scarring tHR: 6.3, 95% CI: 1.4 to 28.0, p 0.02) (Fig. 2A). Despite
n LVEF 30%, the high-risk subcohort with scar 5%
ad an event rate similar to the entire group with LVEF
30% (HR: 0.8, 95% CI: 0.4 to 1.6, p  0.56). Similar
elationships were observed for the secondary endpoints
Figs. 2B and 2C).
Among patients with LVEF30%, again those with scar
5% had higher incidence of death or ICD discharge
ompared with those with scar 5% (HR: 3.9, 95% CI: 1.2
o 13.1, p  0.03) (Fig. 3A). Similar trends were found for
he secondary endpoints, but these did not reach statistical
ignificance (Figs. 3B and 3C). Despite an LVEF 30%, the
ow-risk subcohort with scar 5% had an event rate (for all 3
ndpoints) similar to the entire group with LVEF 30%.
Survival analysis with an LVEF cutoff of 35% (rather
han 30%) demonstrated similar findings. Despite an LVEF
35%, those patients with scar 5% had an event rate
imilar to the entire group with LVEF 35% (HR: 0.6,
5% CI: 0.3 to 1.5, p  0.29). Conversely, among patients
ith an LVEF 35%, the subgroup of patients with scar
5% had an event rate similar to the entire group with
VEF 35% (HR: 0.8, 95% CI: 0.2 to 2.8, p  0.69).
igure 4 illustrates typical cardiac MRI images in patients
ith various levels of myocardial scarring and LV function.
car morphology and events. A number of characteristics
f scar morphology were evaluated, and their relationships
o outcome are shown in Table 3. Many parameters were
ssociated with adverse outcome (primary and both second-
ry endpoints) on an unadjusted basis. However, a multi-
ariable analysis including only scar morphology covariates,
emonstrated that scar size 5% (p  0.03, HR: 3.1, 95%
I: 1.1 to 8.6) and the number of separate scars (p  0.02,
R: 1.7, 95% CI: 1.1 to 2.5) were independent predictors of
cardioverter-defibrillator (ICD) discharge is shown according to different levels of
ndline (red line) shows a positive slope over the entire range, indicating that
in event rate is noted for scar size 5% of left ventricular (LV) mass, which how-ntable
the tre
ep-uphe primary endpoint.
Clinical and Cardiac MRI Predictors of Time to EventTable 2 Clinical and Cardiac MRI Predictors of Time to Event
Death or ICD Discharge SCD or ICD Discharge Death
Univariable Multivariable Univariable Multivariable Univariable Multivariable
Parameter* HR (95% CI) p Value HR (95% CI) p Value HR (95% CI) p Value HR (95% CI) p Value HR (95% CI) p Value HR (95% CI) p Value
All (n  137)
Clinical
Male — — — — — — — — 3.43 (1.00–11.80) 0.05 — —
Ischemic heart disease 1.98 (1.01–3.86) 0.05 — — — — — — 3.76 (1.25–11.33) 0.02 — —
Diabetes mellitus 1.81 (0.93–3.53) 0.08 — — — — — — 3.51 (1.43–8.66) 0.006 — —
NYHA functional class 1.81 (1.29–2.56) 0.0007 1.70 (1.19–2.41) 0.003 1.50 (1.01–2.21) 0.042 — — 2.86 (1.65–4.96) 0.0002 2.19 (1.29–3.70) 0.004
Beta-blocker 2.12 (0.97–4.62) 0.06 — — — — — — — — — —
Heart rate (beats/min) 1.017 (0.997–1.038) 0.10 — — — — — — 1.05 (1.02–1.08) 0.0004 1.05 (1.02–1.08) 0.002
QRS (ms) — — — — — — — — 1.01 (1.00–1.02) 0.09 — —
Cardiac MRI
LVEF (%) 0.971 (0.952–0.991) 0.005 — — 0.977 (0.955–0.999) 0.04 — — 0.957 (0.927–0.989) 0.009 — —
LVEF 30% 2.17 (1.13–4.17) 0.02 — — 1.73 (0.83–3.63) 0.15 — — 2.56 (0.97–6.73) 0.06 — —
LVEF 35% 2.65 (1.26–5.60) 0.01 — — 2.11 (0.93–4.78) 0.07 — — 4.16 (1.21–14.28) 0.02 — —
LV EDV (ml) 1.003 (1.001–1.006) 0.03 — — 1.003 (1.000–1.006) 0.06 — — 1.006 (1.003–1.009) 0.0004 — —
LV ESV (ml) 1.003 (1.001–1.006) 0.01 — — 1.003 (1.001–1.006) 0.04 — — 1.006 (1.003–1.009) 0.0002 — —
LV mass (g) — — — — — — — — 1.005 (0.999–1.010) 0.09 — —
LV aneurysm — — — — 2.65 (1.08–6.51) 0.03 — — — — — —
Any scar on DE-CMR 6.15 (1.48–25.5) 0.01 — — 4.50 (1.07–18.9) 0.04 — — NA† NA† — —
Scar size (% LV mass) 1.038 (1.008–1.069) 0.01 — — 1.038 (1.003–1.074) 0.03 — — — — — —
Scar size 5% 5.18 (2.02–13.3) 0.0006 4.59 (1.79–11.8) 0.002 4.76 (1.65–13.7) 0.004 4.76 (1.65–13.7) 0.004 5.89 (1.36–25.5) 0.02 8.75 (1.89–41.0) 0.006
EPS subgroup (n  105)
Clinical
Ischemic heart disease 2.20 (1.02–4.73) 0.04 — — — — — — 3.85 (1.06–13.99) 0.04 — —
Cigarette smoker — — — — 2.23 (0.91–5.46) 0.08 — — — — — —
Diabetes mellitus — — — — — — — — 2.94 (0.99–8.76) 0.05 — —
NYHA functional class 1.66 (1.11–2.50) 0.01 1.53 (1.00–2.33) 0.05 — — — — 2.32 (1.23–4.43) 0.009 — —
Heart rate (beats/min) 1.02 (1.00–1.04) 0.05 — — — — — — 1.05 (1.02–1.09) 0.0006 1.06 (1.03–1.10) 0.0006
QRS (ms) 1.011 (1.000–1.021) 0.05 — — — — — — 1.018 (1.003–1.033) 0.02 — —
LBBB — — — — — — — — 3.14 (0.96–10.24) 0.06 — —
EPS
Monomorphic VT 2.47 (1.15–5.30) 0.02 — — 3.26 (1.39–7.63) 0.007 — — — — — —
Cardiac MRI
LVEF (%) 0.972 (0.950–0.994) 0.01 — — 0.977 (0.950–1.002) 0.07 — — 0.965 (0.930–1.000) 0.05 — —
LVEF 30% 2.25 (1.06–4.78) 0.03 — — 2.00 (0.86–4.69) 0.11 — — 2.06 (0.67–6.26) 0.21 — —
LVEF 35% 2.31 (1.02–5.22) 0.04 — — 1.90 (0.77–4.66) 0.16 — — 2.86 (0.79–10.41) 0.11 — —
LV EDV (ml) — — — — — — — — 1.004 (1.001–1.008) 0.01 — —
LV ESV (ml) 1.003 (1.000–1.006) 0.08 — — — — — — 1.005 (1.001–1.008) 0.01 — —
LV aneurysm — — — — — — — — NA‡ NA‡ — —
Any scar on DE-CMR 6.37 (1.51–26.8) 0.01 — — 4.72 (1.10–20.18) 0.04 — — NA† NA† — —
Scar size (% LV mass) 1.034 (1.001–1.067) 0.04 — — 1.033 (0.996–1.071) 0.08 — — — — — —
Scar size 5% 5.16 (1.97–13.6) 0.0009 4.36 (1.65–11.6) 0.003 4.83 (1.63–14.3) 0.004 4.83 (1.63–14.3) 0.004 5.28 (1.17–23.8) 0.03 5.81 (1.26–26.8) 0.02
*Only parameters with p  0.10 for one or more endpoints are shown; only variables with p  0.10 by univariable analysis were considered for inclusion in the multivariable model. †Not available because all patients who died had scar tissue. ‡Not available because no
patient in the electrophysiology study (EPS) subgroup who died had an LV aneurysm.
CI  confidence interval; HR  hazard ratio; SCD  sudden cardiac death; other abbreviations as in Table 1.
414
Klem
etal.
JACC
Vol.60,No.5,2012
M
yocardialScarring
and
ICD
Risk
Stratification
July
31,2012:408–20
415JACC Vol. 60, No. 5, 2012 Klem et al.
July 31, 2012:408–20 Myocardial Scarring and ICD Risk StratificationDiscussion
The main finding of this study is that myocardial scarring
detected by DE-CMR strongly predicts death or appropri-
ate ICD discharge for sustained ventricular arrhythmia in
patients undergoing evaluation for possible ICD placement.
On multivariable analysis, which included LVEF and elec-
trophysiological study results, scar size was an independent
predictor of adverse outcome when considered as a contin-
uous variable or dichotomized at 5% of LV mass. For the
latter, the HR was 4.6, 95% CI: 1.8 to 11.8, in all patients
and 4.4, 95% CI: 1.7 to 11.6, in patients undergoing EPS
(n  105). Furthermore, scar size 5% was an independent
predictor of both secondary endpoints, SCD or ICD dis-
charge and all-cause mortality alone.
Scar tissue is believed to be a fundamental component of
the anatomical substrate for lethal ventricular arrhythmias
(10–13,43). In the setting of coronary disease, electrical
mapping studies have revealed that reentrant VT usually
originates from the subendocardial surface of infarcted
Figure 2 Kaplan-Meier Estimates of Adverse Events in Patients
In patients with left ventricular ejection fraction (LVEF) 30%, those with significan
mal or no scarring (5%) for both the primary (A) and the 2 secondary endpoints
entire group of patients with LVEF 30%. *For the secondary endpoint of death a
30%, cannot be calculated because there were no deaths in the latter group. CI
diac death.myocardium, adjacent to dense scar (11,43,44). In thesetting of nonischemic cardiomyopathy, scar is less com-
mon, and some characteristics are different (less confluence,
less endocardial involvement) (17,45,46), but again VT
seems primarily the result of myocardial reentry associated
with scar (13,47). In both settings, histological analysis of
myocardial specimens have shown that regions that are
crucially involved in the reentry circuit consist of isolated
bundles of surviving myocytes interwoven with strands of
fibrous scar tissue—the consequence of which is non-
uniform anisotropic conduction and other electrophysiolog-
ical abnormalities that can result in VT (11,12,43).
The potential relevance of scar as detected by DE-CMR
was initially investigated by comparisons with electrophys-
iological testing. Bello et al. (34) observed that infarct scar
size (or surface area) was a better predictor of inducible
monomorphic VT on EPS than LVEF in patients with
coronary disease. Similarly, Nazarian et al. (48) demon-
strated that DE-CMR assessment of scar distribution was
the strongest predictor of inducible VT in patients with
LVEF >30%
ring (5% of left ventricular mass) had a higher event rate than those with mini-
. Those with LVEF 30% and significant scarring had event rate similar to the
he hazard ratio (HR) between scar 5%, LVEF 30%, and scar 5%, LVEF
fidence interval; ICD  implantable cardioverter-defibrillator; SCD  sudden car-With
t scar
(B, C)
lone, t
 connonischemic cardiomyopathy. More recently, in patients
416 Klem et al. JACC Vol. 60, No. 5, 2012
Myocardial Scarring and ICD Risk Stratification July 31, 2012:408–20referred for radiofrequency ablation of VT or symptomatic
premature ventricular complexes, Bogun et al. (46) reported
that DE-CMR diagnosed scar in all patients with history of
sustained VT; and when a critical site of VT was identified,
it occurred within areas of scar in all cases. Moreover, the
location of scar was a reliable guide to catheter ablation—for
predominantly endocardial scar, an endocardial approach
was necessary, for epicardial scar, an epicardial approach was
needed, and for mid-wall intramural scar, ablation was
uniformly ineffective. Thus, these data present compelling
evidence that DE-CMR–identified scar is associated with
ventricular arrhythmias and offer mechanistic insight into
why scar assessment might be better at predicting prognosis
than LVEF or indexes of LV morphology.
The results of the present study corroborate and extend
those of earlier reports investigating the prognostic significance
of scarring identified by DE-CMR (19,21,22,24,49,50).
These studies have consistently demonstrated the additive
value of scar (or infarct) assessment for predicting adverse
outcome. However, most studies had few hard endpoints
(19,23,24) and/or were retrospective evaluations of patients
Figure 3 Kaplan-Meier Estimates of Adverse Events in Patients
In patients with LVEF 30%, those with significant scarring (5% of LV mass) had
(A) and the 2 secondary endpoints (B, C). Those with LVEF 30% and minimal or
Abbreviations as in Figure 2.who had undergone clinically ordered cardiac MRI in whichscan results were used to determine patient management
(21,49,50). In the current study, all patients were prospec-
tively enrolled before cardiac MRI, and in most (80%)
cardiac MRI was performed only for research purposes, and
scan results were not used to guide clinical decision-making.
The overall crude mortality rate of 6.8%/year was similar to
that in comparable populations at risk for arrhythmia (3,5),
and 39 patients reached the pre-specified primary endpoint of
death or appropriate ICD discharge. Although still relatively
small, the number of events compares favorably with recently
published prospective cardiac MRI studies by Wu et al. (23),
Assomull et al. (19), and Wu et al. (24), which involved 18, 23,
and 15 events, respectively, overall and 2, 10, and 7 events after
excluding hospitalization events.
The present study is the first to directly compare cardiac
MRI scar assessment with invasive EPS for predicting prog-
nosis. EPS has distinct advantages over LVEF in that the
actual induction of VT directly establishes the presence of an
arrhythmic substrate and is more specific for predicting an
arrhythmic death (51) and a risk stratification strategy involv-
ing EPS has higher efficiency (fewer ICDs needed/life saved)
LVEF <30%
her event rate than those with minimal or no scarring (5%) for both the primary
arring had similar event rate to the entire group of patients with LVEF 30%.With
a hig
no scthan one focused primarily on LVEF (52). Nonetheless, a
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likelihood for arrhythmic death, especially in patients with low
LVEF or with nonischemic cardiomyopathy (37,52,53). In our
relatively broad patient population we observed that inducibilty
of VT on EPS was a significant univariable predictor of adverse
events, but on multivariable analysis DE-CMR scar assess-
ment was superior to EPS in predicting both primary and
secondary endpoints.
Clinical implications. Although significant LV dysfunc-
tion identifies a cohort at particularly high risk for SCD, it
is a well-recognized paradox that most patients that die
suddenly have less severe dysfunction. For instance, the
Maastricht prospective registry found that 81% of patients
experiencing SCD had an LVEF 30% before the event
(54). Likewise, the Oregon sudden death study reported
Figure 4 Typical CMR Images in Patients With Various Levels
Example cardiovascular magnetic resonance (CMR) images are shown in patients
ment of risk as determined by LVEF and myocardial scarring (yellow arrows). The
when available. Patient A had poor LVEF and substantial scarring. This patient, wh
tachycardia (VT) during the first month of follow-up. Conversely, Patient B had poo
parameters. This patient received an ICD on the basis of LVEF criteria but had no
those with significantly higher LVEF (46% and 49%, respectively) in whom there wa
artery disease–type scarring (involves left ventricular subendocardium), whereas P
endocardium). Both patients had events during follow-up (Patient C: sudden cardia
minate VT at 1 month and again at 10 months of follow-up). SR  sinus rhythm; othat 70% of patients suffering SCD had an LVEF 35%before the event. The present investigation was not a
community-wide population study, but it is notable that, of the
72 patients that would have been considered low-risk solely
from an LVEF perspective (LVEF 30%), 14 died or had an
appropriate ICD discharge during follow-up. Importantly, scar
5% on DE-CMR classified 12 of these 14 as high- rather
than low-risk individuals. The DE-CMR images of 2 of these
patients are shown in Figure 4 (Patients C and D).
By contrast, it is also recognized that, among patients that
meet the current definition of high-risk LVEF (30%-
35%), most will not derive any benefit from ICD implan-
tation, because 14 to 18 patients with high-risk LVEF need
to have an ICD inserted to prevent 1 death (3,5). In the
present study 65 patients had LVEF 30%, among whom
25 died or had an appropriate ICD discharge during
ocardial Scarring and Left Ventricular Function
ncordance (Patient A) and discordance (Patients B, C, and D) in the assess-
lumn reports findings during follow-up, including the ICD electrograms (EGM)
both parameters concordant for high risk, had an ICD discharge for ventricular
but no myocardial scar, representing discordance in risk between these 2
e events during follow-up (29 months). Patients C and D represent examples of
ordance in risk in that substantial scarring was found. Patient C had coronary
D had non-coronary artery disease–type scarring (spares the left ventricular sub-
th 18 months after study enrollment; Patient D: appropriate ICD discharge to ter-
bbreviations as in Figure 2.of My
with co
last co
o had
r LVEF
advers
s disc
atient
c dea
ther afollow-up. However, those with scar 5% had a 3-year
with C
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Myocardial Scarring and ICD Risk Stratification July 31, 2012:408–20event rate that was below or similar to that of the entire
group with low-risk LVEF (Fig. 3A).
Eligibility for ICD implantation is based primarily on the
presence of LV dysfunction, because LVEF is considered
the strongest independent predictor of SCD among tradi-
tional clinical markers (55). However, our data corroborate
prior investigations reporting that LVEF lacks both sensi-
tivity and specificity in predicting clinical events (55).
Although preliminary, our findings highlight the potential
of scar assessment by DE-CMR to improve the sensitivity
of risk stratification by identifying patients with relatively
preserved LVEF who nevertheless are at considerable risk
for poor outcome. Because most SCD occurs in patients
with preserved LVEF, substantial effort is justified in
evaluating new noninvasive risk stratification strategies in
this group (55). Our results also suggest that DE-CMR scar
assessment might be useful in identifying patients with low
LVEF who might not benefit from ICD therapy. This
hypothesis requires extensive further testing but seems
warranted, given the substantial cost of ICD therapy and
the potential for harm, from unnecessary shocks, procedural
complications, manufacturer recalls, and possible proar-
rhythmia (56).
Study limitations. There are limitations in using ICD
discharges—even after classification as appropriate or not
on the basis of stored electrograms—as a surrogate for SCD
(57). However, our findings were similar when using all-
cause mortality as the endpoint (Table 2), and we believe
the main associations between scar and adverse outcome in
the study are unlikely to be spurious.
We compared scar with LVEF, EPS, QRS duration, and
many other clinical indexes, but several others with high
potential for improving risk stratification, such as T-wave
Relationship of Scar Morphology Variables With Time to EventTable 3 Relationship of Scar Morphology Variables With Time t
Death or ICD Discharge
Univariable
Parameter HR (95% CI) p
Any scar 6.15 (1.48–25.53) 0
CAD type† 5.69 (1.33–24.39) 0
Non-CAD type‡ 4.71 (1.02–21.82) 0
Scar size (% of LV mass) 1.04 (1.01–1.07) 0
Scar size 5% 5.18 (2.02–13.25) 0
Scar surface area (cm2) 1.005 (1.001–1.008) 0
Number of separate scars 2.07 (1.46–2.94) 0
Largest separate scar size (% of LV mass) 1.03 (1.00–1.06) 0
Largest separate surface area (cm2) 1.004 (1.000–1.008) 0
Segments with transmural scar (75%) 1.06 (0.85–1.32) 0
Segments with transmural scar (50%) 1.07 (0.93–1.25) 0
Segments with non-transmural scar (1%–50%) 1.13 (1.04–1.22) 0
Segments with non-transmural scar (26%–75%) 1.17 (1.04–1.31) 0
Gray zone (% of LV mass) 1.011 (0.994–1.027) 0
*Not available because all patients who died had scar tissue. †CAD-type scar required involvement o
or epicardial scar was considered non-CAD type. Hazard ratios were calculated excluding patients
Abbreviations as in Tables 1 and 2.alternans and heart rate variability, were not tested. Asystematic comparison between scar and these other risk
metrics was beyond the scope of the present study but would
be an important area of future research.
An exploratory analysis of scar morphology (Table 3)
suggests that other characteristics besides size might be
important for risk stratification, such as the number of
separate scars, but this will require prospective testing to
fully explore their significance. There are several ways to
quantitatively assess the gray zone, and it is possible that a
different analysis method than the one used in the present
study might have provided different results. Likewise, there
might be different thresholds in scar size to optimally
stratify risk when considering CAD and non-CAD patients
separately. Interestingly, we note that Assomull et al. (19)
found that scar 4.8% was the optimal threshold to predict
outcome in patients with nonischemic cardiomyopathy,
similar to the results of the present study, and Kwong et al.
(21) observed a sharp step-up in risk with even a small
amount of scarring in patients with coronary disease. It is
speculative, but these results are consistent with experimen-
tal investigations that have suggested that a “critical mass” of
scar is necessary for reentrant VT to occur (58,59).
Finally, an important limitation is that the conclusions
are based on a limited number of events (the primary
endpoint occurred in 39 patients), and this raises the
possibility of overfitted multivariable models; larger studies
are vital to confirm these findings.
Conclusions
In patients undergoing evaluation for possible ICD implan-
tation myocardial scarring detected by DE-CMR predicts
nt
SCD or ICD Discharge Death
Univariable Univariable
HR (95% CI) p Value HR (95% CI) p Value
4.50 (1.07–18.89) 0.04 NA* NA*
4.02 (0.91–17.76) 0.07 NA* NA*
3.23 (0.65–16.02) 0.15 NA* NA*
1.04 (1.00–1.07) 0.03 1.03 (0.99–1.08) 0.20
4.76 (1.66–13.69) 0.004 5.89 (1.36–25.48) 0.02
1.005 (1.001–1.009) 0.03 1.006 (1.001–1.011) 0.03
1.91 (1.28–2.87) 0.002 3.11 (1.83–5.28) 0.0001
1.03 (1.00–1.07) 0.08 1.01 (0.96–1.06) 0.70
1.005 (1.000–1.009) 0.06 1.003 (0.997–1.009) 0.40
1.11 (0.87–1.41) 0.40 0.80 (0.51–1.26) 0.30
1.10 (0.93–1.29) 0.30 0.90 (0.69–1.17) 0.40
1.10 (1.00–1.22) 0.05 1.18 (1.05–1.32) 0.007
1.17 (1.02–1.34) 0.02 1.07 (0.89–1.29) 0.50
1.003 (0.980–1.026) 0.81 1.019 (1.000–1.039) 0.052
bendocardium; HRs were calculated excluding patients with non-CAD type scar. ‡Isolatedmid-wall
AD type scar.o Eve
Value
.01
.02
.05
.01
.0006
.008
.0001
.09
.06
.60
.40
.005
.01
.20
f the suworse outcome. Even in patients with LVEF 30% con-
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1
2
2
2
2
2
2
2
2
2
2
3
3
3
3
3
3
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July 31, 2012:408–20 Myocardial Scarring and ICD Risk Stratificationsidered low-risk from an LVEF perspective, significant
scarring (5%) identifies a cohort with a high rate of
adverse events and one similar in risk to those with LVEF
30%. Additionally, in patients with LVEF 30%, mini-
mal or no scarring identifies a cohort with lower risk similar
those with LVEF 30%. The findings suggest that DE-
CMR scar assessment is superior to LVEF for risk stratifi-
cation and justify future studies prospectively testing
whether patient management guided by cardiac MRI find-
ings can improve patient outcome.
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